Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
List view / Grid view
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
The Atlas of Variant Effects Alliance will develop a map of human genetic variants to advance the understanding and treatment of disease.
Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
Don’t miss the latest product hub from Fluidic Analytics, detailing the Fluidity One-W Serum which enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Several recent studies highlight the promise of combining genomics and proteomics to uncover new, robust drug targets.
Researchers have used imaging mass cytometry to analyse the cellular landscape of diseased lung tissue in severe COVID-19, revealing insights into the disease.
The isolation of microbial DNA is a key prerequisite for determining the microbiome profile of each body habitat.
Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
Professor David Merryman explains how his team targeted the serotonin 2B receptor in animal models to preserve cardiac function six weeks after a heart attack.